Randomized, crossover, two-period, comparative bioavailability study of two ibuprofen (arginate) formulations, administered as solutions in single oral dose of 400 mg to healthy subjects under fasting conditions.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514478-37-00

Acronym

FMLD- IOSOL-61

Enrollment

Registered

2024-09-30

Start date

2024-10-04

Completion date

2024-11-20

Last updated

2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026